T1	Participants 149 199	recurrent or refractory non small-cell lung cancer
T2	Participants 932 1054	All patients had histologically confirmed nonsquamous NSCLC that had progressed during or after one platinum-based regimen
T3	Participants 1064 1126	One hundred twenty patients were randomly assigned and treated
